Coronavirus disease (COVID-19) infection was declared a public health emergency of
international concern in January 2020. The medical literature has since seen a succession …

Rationale: Pneumococcal pneumonia remains a global health problem. Pneumococcal
colonization increases local and systemic protective immunity, suggesting that nasal …

Introduction Pneumococcal colonisation is regarded as a pre-requisite for developing
pneumococcal disease. In children previous studies have reported pneumococcal …

Rationale: Streptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive
pneumococcal disease and associated with low carriage rates. Following the introduction of …

Pneumococcal conjugate vaccine (PCV) efficacy is lower for noninvasive pneumonia than
invasive disease. In this study, participants were immunized with 13-valent PCV (PCV13) or …

Pneumococcal conjugate vaccine efficacy is lower for non-invasive pneumonia than
invasive disease. In this study, participants were vaccinated with PCV13 or HepA (control) …

Introduction & Aim: In the UK there are 4 monoclonal antibodies (MAbs) approved to treat
severe asthma. We aim to describe the efficacy of these agents in real world clinical practice …

We read with interest the communication from Rappaport and colleagues describing their
experience measuring anti–factor Xa (FXa) activity in critically unwell patients with …

Introduction: 267 patients receive a variety of biologic therapies for severe asthma at our
centre. The Covid-19 pandemic accelerated our efforts to facilitate patients' receiving these …